SAB Biotherapeutics (SABS) Competitor Comparison
We are evaluating the key criteria listed to compare SAB Biotherapeutics (SABS) against its competitors in the Biotechnology industry.
Market Capitalization
298 / 368Gross Profits
163 / 278Total Revenue
206 / 300EBITDA
98 / 337Free Cashflow
71 / 352Quick Ratio
349 / 357Earnings per Share
323 / 359Dividend yield
0 / 6Total Cash
341 / 358Performance 3 years
353 / 368Performance 5 years
341 / 368Performance 10 years
307 / 368Linearity 3 years
323 / 368Linearity 5 years
277 / 368Linearity 10 years
241 / 368Total Rank
253 / 368Dividend Rank
13 / 368Valuation Rank
104 / 368Piotroski Rank
310 / 368Muliplier Rank
198 / 368Quick Ratio - SABS ranking 349 / 357
Obligatory risk notice
We would like to point out that the contents of this website are for general information purposes only and do not constitute recommendations for the purchase or sale of specific financial instruments, and therefore do not constitute investment advice. In particular, marketstorylabs.com and its creators cannot assess the extent to which information / recommendations made on the pages correspond to your investment objectives, your risk tolerance and your ability to bear losses. Therefore, if you make any investment decisions based on information on the site, you do so solely on your own responsibility and at your own risk. This in turn means that neither marketstorylabs.com nor its creators are liable for any losses incurred as a result of investment decisions based on the information on the marketstorylabs.com website or other media used.